Impact of metastases on survival 79 CHAPTER 5 Total No metastases History of metastases Synchronous metastases P-value N = 349 N = 261 N = 42 N = 46 121 (34.7) 93 (35.6) 12 (28.6) 16 (34.8) 0.694 228 (65.3) 168 (64.4) 30 (71.4) 30 (65.2) 64 (58-71) 65 (59-72) 62 (58-69) 63 (52-69) 0.074 279 (85.3) 220 (87.3) 26 (78.8) 33 (78.6) 0.186 48 (14.7) 32 (12.7) 7 (21.2) 9 (21.4) 71 (20.7) 60 (23.5) 6 (14.3) 5 (10.9) 0.082 272 (79.3) 195 (76.5) 36 (85.7) 41 (89.1) 151 (44.4) 121 (47.8) 12 (29.3) 18 (39.1) 0.063 189 (55.6) 132 (52.2) 29 (70.7) 28 (60.9) 146 (41.8) 108 (41.4) 11 (26.2) 27 (58.7) 0.036 104 (29.8) 80 (30.7) 14 (33.3) 10 (21.7) 99 (28.4) 73 (28.0) 17 (40.5) 9 (19.6) 13 (3.7) 13 (5.0) 0 (0) 0 (0) 0.011 236 (67.6) 178 (68.2) 22 (52.4) 36 (78.3) 100 (28.7) 70 (26.8) 20 (47.6) 10 (21.7) 285 (81.7) 222 (85.1) 27 (64.3) 36 (78.3) 0.004 64 (18.3) 39 (14.9) 15 (35.7) 10 (21.7) ASA, American Society of Anesthesiologists Physical Status; IQR, interquartile range; LAR, low anterior resection; TEM, transanal endoscopic microsurgery. Local recurrence The 3-year LRFS rate in all patients was 49 percent (median LRFS 31.2 months), and 51 percent, 40 percent, and 46 percent in patients without metastases, with a history of metastases, andwith synchronousmetastases, respectively (P =0.253; Figure 1B). There was no significant difference in the LRFS between patients without metastases and those with a history of metastases (P = 0.116), without metastases versus synchronous metastases (P = 0.437), or a history of metastases versus synchronous metastases (P = 0.550).
RkJQdWJsaXNoZXIy MTk4NDMw